Nageswara Rao Muddana

Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease

Ramakrishna Nirogi, Abdul Rasheed Mohammed, Anil Shinde et al. · European Journal of Medicinal Chemistry · 2015 · 59 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

LC–MS/MS method for the quantification of aldose reductase inhibitor – Epalrestat and application to pharmacokinetic study

Ramakrishna Nirogi, Vishwottam Kandikere, Devender Reddy Ajjala et al. · Journal of Pharmaceutical and Biomedical Analysis · 2012 · 14 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation

Ramakrishna Nirogi, Vijay Benade, Saivishal Daripelli et al. · Psychopharmacology · 2021 · 14 citations

Medicine, Neuroscience, Pharmacology +12

Absorption, distribution, metabolism, excretion (ADME), drug-drug interaction potential and prediction of human pharmacokinetics of SUVN-G3031, a novel histamine 3 receptor (H3R) inverse agonist in clinical development for the treatment of narcolepsy

Ramakrishna Nirogi, Gopinadh Bhyrapuneni, Nageswara Rao Muddana et al. · European Journal of Pharmaceutical Sciences · 2020 · 11 citations

Pharmacy, Pharmacokinetics, Pharmacology +15

Safety, Tolerability and Pharmacokinetics of the Serotonin 5-HT6 Receptor Antagonist, SUVN-502, in Healthy Young Adults and Elderly Subjects

Ramakrishna Nirogi, Koteshwara Mudigonda, Gopinadh Bhyrapuneni et al. · Clinical Drug Investigation · 2018 · 10 citations

Medicine, Pharmacokinetics, Pharmacology +13